Biogen Idec Inc. Message Board

If Azimuth went short on the teva news knowing they had 2 bucks to pocket, the short % of the float just got cut in half., which loosen the anchor. i think gunner and castle called it correctly. the shares are now commited on the long side. which should propel other shorts to cover. they just lost alot of downside momo. pps adjust quckly to the offering price. today was not bad but not ugly within 3.4% of the days prior tape. i hoping thier no more of these circa 2012 deal sheets out there. my guess it there not. the bottom line King had no resposibility to remind us retail guys of the deal from july of last year. i think we start moving up. expect some buyside volume spikes in the next 7 days. looing to breakout above 5 in short order. oh ya , we just 6mm stronger on the balance sheet. no more offering until what 3Q 2014. thats blue skies for a small bio. sorry about typos. goodnite.

you can find them both on the companies website, sec filing , etc. they sold 1.437 mm shares today via a perspectus they shopped in July 2012.

Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 1,437,481 shares of our common stock to Azimuth Opportunity, L.P., or Azimuth, pursuant to a Common Stock Purchase Agreement between us and Azimuth dated as of July 20, 2012, which we refer to as the Purchase Agreement, at a price of approximately $4.48 per share. The total purchase price for the shares is approximately $6.4 million. We will receive net proceeds from the sale of these shares of approximately $6.3 million, after deducting our estimated offering expenses of approximately $0.1 million, including a placement agent fee of $32,200 to be paid to Financial West Group, member FINRA/SIPC, or FWG, in connection with this offering.

This prospectus supplement and the accompanying prospectus also cover the resale of these shares by Azimuth to the public. Azimuth is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act, and any profits on the sales of shares of our common stock by Azimuth and any discounts, commissions or concessions received by Azimuth may be deemed to be underwriting discounts and commissions under the Securities Act.

We expect to issue these shares to Azimuth on or about May 24, 2013. Our common stock is traded on the NASDAQ Global Market under the trading symbol “ALXA.” On May 22, 2013, the last reported sales price for our common stock was $4.67 per share.

while other bio are up 1% for the day. this stock is frustrating the heck out of me. i don't get it. really frustrated. anyone have any ideas... not you betting freddy. you're DD is as deep as a puddle. no offense. darn it.

I urge you to call Mr. KIng CEO of Alexza and ask for him to consider a corporate buyback of shares or some insider purchases from officers, board members directors. Demand it. Shareholders like us have been sitting here way too long without any appreciation. While they ( officers ) recieve bonus and stock grants. 650-944 7000. Call everyday. leave messages. you can also call there IR department at 650 944 7900. Be vocal people be shareholder activist who demand attention to thier investments. Be firm not rude. character counts.

i just checked whalewisdom. it looks like i stand corrected. i checked 13g's and 13f's and came to same conclusion. occitan is flat. now that, i think about it form 4's are for insiders ( board members, executives, etc and 10% owners ) which occitan was not. they had 6%. thanks for taking me back to school Fifebio . i'm so glad to be wrong because helps me understand what happeneded post news. they occitan sold right into the news. Feferbio , do you think we move back up now ? thanks for helping me.